Q2 and Partway Through

EpicentRx is elated despite this newsletter being belated.

It’s already the end of July – how time does fly!

The unquestioned highlight of Q2 – and possibly of all 2024 – was the BOOM! heard ‘round the world from Dr. Anthony P. Conley’s ASCO oral presentation on the transforming growth factor beta (TGFβ) inhibitor, AdAPT-001. Dr. Conley brought down the house – or at least the large auditorium – with clinical images of impressively durable remissions in immunotherapy-resistant “cold” tumors like sarcoma.

Other Q2-worthy news: enrollment continues – hence the title “Q2 and Partway Through” – for the two ongoing late-stage RRx-001 clinical trials, Phase 3 REPLATINUM in 3rd line or beyond small cell lung cancer (SCLC) and the Phase 2b KEVLARx in radioprotection. Also, in start-up for RRx-001 is a Phase 1 endometriosis clinical trial at the University of Edinburgh, Scotland. On the experimental front, Dr. Richard Gordon in Australia continues to deliver impressive data that support the rapid clinical translation of RRx-001 in neurodegenerative diseases like Parkinson’s and ALS/MND.

Meanwhile, Q3 is off to a great start with several promising networking and business development opportunities, the award and submission of new grants, and top-tier conferences like the Society for Neuroscience (SfN) where EpicentRx will present.

Until next time!
The EpicentRx Team